



The legacy of ZikaPLAN: a transnational research consortium addressing Zika

Annelies Wilder-Smith, Elizabeth B. Brickley, Ricardo Arraes de Alencar Ximenes, Demócrito de Barros Miranda-Filho, Celina Maria Turchi Martelli, Tom Solomon, Bart C. Jacobs, Carlos A. Pardo, Lyda Osorio, Beatriz Parra, Suzannah Lant, Hugh J Willison, Sonja Leonhard, Lance Turtle, Maria Lúcia Brito Ferreira, Rafael Freitas de Oliveira Franca, Louis Lambrechts, Johan Neyts, Suzanne Kaptein, Rosanna Peeling, Deborah Boeras, James Logan, Helen Dolk, Ieda M Orioli, Andreas Neumayr, Trudie Lang, Bonny Baker, Eduardo Massad & Raman Preet

To cite this article: Annelies Wilder-Smith, Elizabeth B. Brickley, Ricardo Arraes de Alencar Ximenes, Demócrito de Barros Miranda-Filho, Celina Maria Turchi Martelli, Tom Solomon, Bart C. Jacobs, Carlos A. Pardo, Lyda Osorio, Beatriz Parra, Suzannah Lant, Hugh J Willison, Sonja Leonhard, Lance Turtle, Maria Lúcia Brito Ferreira, Rafael Freitas de Oliveira Franca, Louis Lambrechts, Johan Neyts, Suzanne Kaptein, Rosanna Peeling, Deborah Boeras, James Logan, Helen Dolk, Ieda M Orioli, Andreas Neumayr, Trudie Lang, Bonny Baker, Eduardo Massad & Raman Preet (2021) The legacy of ZikaPLAN: a transnational research consortium addressing Zika, *Global Health Action*, 14:sup1, 2008139, DOI: [10.1080/16549716.2021.2008139](https://doi.org/10.1080/16549716.2021.2008139)

To link to this article: <https://doi.org/10.1080/16549716.2021.2008139>



© 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 04 Apr 2022.



Submit your article to this journal [↗](#)













View related articles [↗](#)



View Crossmark data [↗](#)

The legacy of ZikaPLAN: a transnational research consortium addressing Zika

Annelies Wilder-Smith ^{a,b}, Elizabeth B. Brickley ^c, Ricardo Arraes de Alencar Ximenes^d, Demócrito de Barros Miranda-Filho ^e, Celina Maria Turchi Martelli^f, Tom Solomon^g, Bart C. Jacobs^h, Carlos A. Pardo ⁱ, Lyda Osorio^j, Beatriz Parra^k, Suzannah Lant^g, Hugh J Willison ^k, Sonja Leonhard^h, Lance Turtle^g, Maria Lúcia Brito Ferreira^l, Rafael Freitas de Oliveira Franca^m, Louis Lambrechts ⁿ, Johan Neyts ^o, Suzanne Kaptein ^o, Rosanna Peeling^c, Deborah Boeras^p, James Logan^c, Helen Dolk ^q, Ieda M Orioli ^r, Andreas Neumayr^s, Trudie Lang^t, Bonny Baker^t, Eduardo Massad^u and Raman Preet^a

^aDepartment of Epidemiology and Global Health, Umeå University, Umeå, Sweden; ^bHeidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany; ^cLondon School of Hygiene & Tropical Medicine, London, United Kingdom; ^dDepartamento de Medicina Tropical, Universidade Federal de Pernambuco, Recife, Brazil; ^eDepartamento de Medicina Interna, Universidade de Pernambuco, Recife, Brazil; ^fInstituto Aggeu Magalhães, Fundação Oswaldo Cruz, Recife, Brazil; ^gNIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences University of Liverpool, Liverpool, UK; ^hDepartments of Neurology and Immunology, Erasmus Universitair Medisch Centrum Rotterdam, The Netherlands; ⁱDepartment of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA; ^jUniversidad del Valle, Cali, Colombia; ^kInstitute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK; ^lHospital da Restauração, Recife, Brazil; ^mOswaldo Cruz Foundation, Recife, Brazil; ⁿInsect-Virus Interactions Unit, Institut Pasteur, UMR2000, CNRS, 75015 Paris, France; ^oKU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, Leuven, Belgium; ^pThe Global Health Impact Group, USA; ^qCentre for Maternal, Fetal and Infant Research, Institute for Nursing and Health Research, Ulster University, Ulster, United Kingdom; ^rRELAMC and ECLAMC at Genetics Department, Federal University of Rio de Janeiro, Brazil; ^sDepartment of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland; ^tThe Global Health Network, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK; ^uSchool of Medicine, University of Sao Paulo and Fundacao Getulio Vargas, Sao Paulo, Brazil

ABSTRACT

Global health research partnerships with institutions from high-income countries and low- and middle-income countries are one of the European Commission's flagship programmes. Here, we report on the ZikaPLAN research consortium funded by the European Commission with the primary goal of addressing the urgent knowledge gaps related to the Zika epidemic and the secondary goal of building up research capacity and establishing a Latin American-European research network for emerging vector-borne diseases. Five years of collaborative research effort have led to a better understanding of the full clinical spectrum of congenital Zika syndrome in children and the neurological complications of Zika virus infections in adults and helped explore the origins and trajectory of Zika virus transmission. Individual-level data from ZikaPLAN's cohort studies were shared for joint analyses as part of the Zika Brazilian Cohorts Consortium, the European Commission-funded Zika Cohorts Vertical Transmission Study Group, and the World Health Organization-led Zika Virus Individual Participant Data Consortium. Furthermore, the legacy of ZikaPLAN includes new tools for birth defect surveillance and a Latin American birth defect surveillance network, an enhanced Guillain-Barre Syndrome research collaboration, a de-centralized evaluation platform for diagnostic assays, a global vector control hub, and the REDe network with freely available training resources to enhance global research capacity in vector-borne diseases.

ARTICLE HISTORY

Received 1 July 2021
Accepted 12 November 2021

RESPONSIBLE EDITOR

Stig Wall

KEYWORDS

Zika; congenital Zika syndrome; birth defect; epidemic preparedness; research capacity building; European Commission; microcephaly; Guillain-Barré Syndrome; encephalitis; sustainability

Background

Global health research partnerships are increasingly taking the form of consortia of institutions from high-income countries and low- and middle-income countries that undertake programs of research. These partnerships differ from collaborations that carry out single projects in their manifold variety of goals, activities, including the nature of their management [1]. Such consortia primarily aim to enhance research collaboration between and within countries and continents by facilitating access to patient cohorts for shared data analyses, leveraging upon the strength of multidisciplinary and international research approach, and building up

collaborative networks between research institutions across the globe.

After a cluster of children born with abnormally small head circumferences was detected in northeast Brazil in late 2015, and a public health emergency declared in early 2016 [2], the European Commission awarded three research consortia with global health research partnerships to urgently address the knowledge gaps related to Zika virus infections, and form a research network with Latin America. ZikaPLAN stands for 'Zika Preparedness Latin American Network' and was one of the three consortia [3]. ZikaPLAN is a consortium with more than 100 researchers from 26 institutions from Belgium, Brazil,

Colombia, Cuba, France, Senegal, Switzerland, The Netherlands, UK, and USA, coordinated by the University of Umeå in Sweden. It is interlinked with the other two EU funded consortia ZIKAlliance and ZIKAction through co-managed and cross-cutting three joint work packages related to communication, management, ethics, networking and cohort studies. A detailed description on the geographic distribution and work packages was published at the beginning of the project [3] with a further mid-term update [4].

The ZikaPLAN project started in October 2016 and came to an end in May 2021. In this article, we exemplify the key learnings, achievements and impact of ZikaPLAN with a focus on the clinical and public health work, drawing upon the networks and resources as well as more than one hundred ZikaPLAN publications to date (available at the project website <https://zikaPLAN.tghn.org/publications/>).

A Addressing congenital Zika syndrome

The etiologic agent triggering the epidemic of microcephaly cases was initially an open question [5,6]. A series of epidemiological studies advanced scientific thought by connecting the microcephaly cases to Zika virus (ZIKV) infections in pregnancy [7–9], ruling out alternative hypotheses, such as larvicide [10] and providing the first clinical description of a new disease, congenital Zika Syndrome [11,12]. As part of the response to the epidemic, teams of investigators based in the Brazilian states of Pernambuco, Rio de Janeiro, and Goiás initiated, with support from the ZikaPLAN Consortium and the Brazilian government, a series of prospective cohort studies of pregnant persons with rash and children with Congenital Zika Syndrome (CZS) to elucidate the risks associated with maternal ZIKV infections.

Pregnancy cohort & vertical transmission studies

To identify cases of acute maternal Zika virus (ZIKV) infections, the Microcephaly Epidemic Research Group (MERG) in Pernambuco State described the serological markers of ZIKV and dengue virus (DENV) among mothers and neonates [7,8,13] and tested participants in the MERG Pregnant Women Cohort. The former study showed a high frequency of ZIKV exposure among mothers of microcephalic neonates and distinct patterns of ZIKV and DENV immune responses, as discernible by the neutralization test [13]. In the latter, women were tested at up to three timepoints during and after pregnancy using a combination of molecular and serologic assays, and the results were integrated in an evidence-graded diagnostic algorithm [14]. Among the pregnancies with suspected or confirmed ZIKV infections, 20% of ZIKV-exposed offspring presented with at least

one clinical feature compatible with CZS, with absolute risks for microcephaly of 3%, neuroimaging abnormalities of 7%, neurologic abnormalities of 5%, and ophthalmologic abnormalities of 7% [15]. Interestingly, vertical transmission of ZIKV, placental features, and neurodevelopmental outcomes can be discordant between co-twins [16].

ZikaPLAN found low sensitivity of both ultrasonography [17] and amniocentesis [18] for prenatal CZS screening and affirmed the importance of comprehensive clinical assessment of neonates with suspected and confirmed ZIKV exposure during pregnancy. Sixty-five per cent of evaluable infants born to PCR-positive mothers were found to have serologic or molecular evidence of vertical transmission when tested within the first three months of life, with decreasing vertical transmission rates over the three trimesters (78% in first, 64% in second, and 48% in third) [19]. A similar temporal pattern was apparent in the frequency of children born small for gestational age and/or with symptoms consistent with CZS, with the highest rates of adverse outcomes in children born to women reporting rash (i.e. a common sign of acute ZIKV infection) in the first trimester [20]. Relative to ZIKV-negative neonates, ZIKV-positive neonates have a 5-times higher risk of presenting with microcephaly [21]. Lower socioeconomic position (i.e. indicated by lower maternal education, lower household income, and higher household crowding) was associated with increased odds of a child being born with congenital microcephaly [22]. Families residing in areas with poor living conditions had a higher prevalence of microcephaly compared with populations with better living conditions [23].

Observational studies of children with congenital Zika syndrome

The ZikaPLAN studies provided unique insights regarding the natural history of CZS. Of note, the MERG pediatric cohort is one of the largest single cohort studies of children with CZS in the world. The MERG pediatric cohort study published several case series reporting on microcephaly [24], prenatal and postnatal brain imaging abnormalities [25,26], oropharyngeal dysphagia [27], early epilepsy [28,29] and rare complications such as cryptorchidism [30,31], endocrine dysfunctions [32], and adenoid hypertrophy [33] over the first years of life. Longer term follow-up of the prenatally exposed infants also found markedly elevated frequencies of seizures, ophthalmologic abnormalities, and hearing deficits in infants born with microcephaly or born small for gestational age relative to exposed infants born without microcephaly and normal or large for gestational age [34]. High frequencies of structural abnormalities and neurodevelopmental delays [35], as well as adverse outcomes

detected using the General Movement Assessment tool [36], were also identified in ZIKV-exposed children born without microcephaly. Observations from this cohort have also shed light on the impacts of CZS on early nutrition and growth for ZIKV-exposed infants, including decreasing weight-for-age Z-scores in the first 14 days of life for hospitalized neonates [37], low rates of exclusive breastfeeding, altered body composition with a lower fat-free mass [38], and worsening anthropometric profiles by 12–23 months of age [39].

As the children in our cohorts have reached pre-school age and beyond, new research is shedding light on the neurodevelopment of children with prenatal ZIKV exposure. A cross-sectional study of 274 children who were evaluated using the Survey of Wellbeing of Young Children neurodevelopment and behavior-screening instrument reported an association between a child's head circumference and their likelihood of being 'at risk of developmental delay,' with 99% 'at risk' in the severe microcephaly group, 65% in the moderate microcephaly group, 14% in the ZIKV-exposed without microcephaly group, and 22% in the unexposed, neurotypical control group [40]. Furthermore, a cross-sectional study of 94 children found that ZIKV-exposed children with normal findings upon brain imaging had reduced odds of severe developmental delay, as indicated by a Bayley-III score of 70 or less, relative to children with abnormal neuroimaging (odds ratio, 95% confidence interval: 0.80, 0.70 to 0.91) [41]. Using the Bayley-III assessments provided evidence of a high frequency of developmental delays, particularly in the language domain, among children with prenatal ZIKV exposure but who were born without apparent symptoms of CZS at birth [42] and potential effect modification on the association between prenatal ZIKV exposure and neurodevelopment by socioeconomic position [22].

Social impacts of congenital Zika syndrome

Between May 2017 and January 2018, ZikaPLAN undertook a series of in-depth qualitative interviews and a cross-sectional study to understand the social and economic impact of CZS in Pernambuco and Rio de Janeiro, Brazil [43,44]. Interviews with mothers suggest that the birth of a child with CZS can be conceptualized as a biographical disruption, requiring a reconfiguration of mothers' and caregivers' support systems and subsequent identities [45]. Interviews with caregivers and healthcare providers also highlighted gender inequalities in caregiving and bottlenecks in accessing healthcare services for children with disabilities [46] and reinforced the importance of trust and co-created hope in the acceptance of therapeutic interventions for children with CZS [47]. The cross-sectional study indicated that more than half of mothers of children with CZS reported at least mild levels of depression (51%), anxiety (53%), and stress (60%), all

of which occurred at higher crude frequencies than among caregivers of children without disabilities [48].

Prevention of congenital Zika syndrome

In response to the CZS threat, vector control and bite-prevention strategies are among the limited options currently available [49]. Pregnant women individual protection by use of repellent or wearing repellent-treated materials is likely to be a challenge even in the presence of enhanced messaging and education. Focus group discussions with pregnant women, women of child-bearing age and their male partners in Colombia highlighted significant gaps in the knowledge of key aspects of Zika disease and bite-prevention, lack of awareness of disease risk and misconceptions about repellent safety. However, health workers were identified as trusted sources of bite-prevention education, suggesting the need to equip them to deliver clear risk-benefit information of approved repellents [50].

Data synthesis & sharing with international partnerships and WHO

In addition to reporting on the findings from individual cohorts, our team of investigators has also been actively engaged in wider evidence synthesis and data sharing efforts, leading to two systematic reviews [51,52] and contributing to four critical commentaries [6,53–55] and three planned individual participant data meta-analyses. The first systematic review collates evidence from 34 studies of ZIKV co-infections, and suggests that, while ZIKV co-infections, especially with other arboviruses, are frequently reported, they do not appear to materially alter the clinical presentation or enhance the severity of uncomplicated acute ZIKV disease [51]. The second systematic review of 32 studies on postnatal ZIKV infections in children and adolescents highlights the scant evidence base in this age range and the need for population-based studies quantifying the associations of pediatric ZIKV infections, especially those occurring in infancy, with neurologic complications and later neurodevelopmental outcomes [52]. Individual-level data from our cohort studies has also been shared for joint analyses as part of the Zika Brazilian Cohorts Consortium [56], the European Commission-funded Zika Cohorts Vertical Transmission Study Group [57], and the World Health Organization-led Zika Virus Individual Participant Data Consortium [58,59]. Joint analyses are ongoing.

In summary, ZikaPLAN has yielded some of the most robust estimates to date of the absolute risks associated with congenital Zika virus infections and provided unique insights regarding the prognosis and

health needs of children born with Congenital Zika Syndrome.

B Setting up birth defect surveillance in Latin America

The Zika outbreak created more awareness about the need for effective sharing of documentary, software, online and training resources related to birth defects surveillance and research. In December 2018, the International Committee for Congenital Anomaly Surveillance Tools (comprising members from Europe, Latin America, Africa, Asia and the USA) was launched. The Global Birth Defects (GBD) website (<https://globalbirthdefects.tghn.org/>) is fully established. It hosts an inventory of existing birth defect surveillance resources as well as information on the Global Birth Defects Description and Coding App. This website nests within The Global Health Network (TGHN) website. The inventory of the GBD website covers a wide range of resources related to birth defects surveillance/research, prevention and care, in eight sections.

The Global Birth Defects Description and Coding (GBDDC) App is a companion tool that can be used by a wide range of health professionals contributing to birth defect surveillance, research and training in low resource settings [60]. It is designed to assist with the description and coding of major externally visible birth defects during the neonatal period. Special modules relate to microcephaly and Congenital Zika Syndrome diagnosis. It is not intended to replace referral of the baby for clinical diagnosis or to inform care options requiring clinical input. The GBDDC App has been designed in two versions:

- the Basic Version designed for use by persons with an interest in understanding/improving birth defect diagnosis or coding, including for training purposes,
- the Surveillance Version which is an extension of the basic version that allows recording of anonymous data for each baby for use in surveillance/research systems.

The App has been translated into Spanish and Portuguese. The Basic Version of the App was launched in October 2019, is now available for download in the Google play store and Apple store, with adaptations possible to suit specific needs. The GBDDC App will be taken over by WHO to form part of the Birth Defects Surveillance toolkit. For reaching various stakeholders and communities, a short video ‘Innovation through Collaborations’ was produced where GBDDC is featured (<https://www.youtube.com/watch?v=Mdf7F8i7azg&t=5s>) (Table 1).

ZikaPLAN enabled the development of a Latin American network of congenital malformation

registries (ReLAMC) [61]. Data sharing rules were established, and this led to the first publication of data on microcephaly and other congenital anomalies from all 12 participating countries for the period 2017–2019, laying the foundation of greater data harmonization in future. Eight RegLAMC registries collaborated in a study of microcephaly and congenital infections with data from the period 2010–2017 (submitted for publication). This showed increases in microcephaly prevalence from two-fold to 70-fold in countries and regions, which experienced the Zika epidemic, with some evidence of improved awareness and reporting of microcephaly continuing beyond the epidemic. The need to collect more data about preventable congenital infections other than Zika was also highlighted for action.

During the Zika pandemic, WHO/PAHO collected notifications of Zika infections and Congenital Zika Syndrome for all countries globally. A summary of these data was collated for the 47 countries in the Americas and the Caribbean, and the strengths and deficiencies of the reporting system were evaluated [62]. By 4 January 2018, 3617 confirmed CZS cases had been reported from 25 countries, 82% from Brazil and 7% from Colombia. There were high CZS rates (above 0.5 per 1000 births) in a number of Caribbean Island communities, with evidence of both severe under-reporting of CZS, and of Zika virus infections among pregnant women.

In summary, ZikaPLAN has enhanced birth defect surveillance in Latin America and beyond by creating and developing networks and producing tools such as the Global Birth Defects Description and Coding App.

C Investigating neurological complications of Zika in adolescents and adults

One of the most prevalent systems seriously affected by ZIKV is the nervous system both through direct infection of foetal and adult neural cells by ZIKV and through immune-mediated damage of the nervous system. In co-operation with the clinical studies conducted within ZikaPLAN, viral isolates, human tissue and blood samples were also collected for laboratory-based investigations into mechanistic pathways underlying the neurological manifestations of ZIKV beyond congenital Zika syndrome. These included exposure of cell lines and neural tissues in the post-neurogenesis time window, *in vitro* and *in vivo*, to ZIKV isolates followed by examination of cell viability, function and downstream molecular cascades. Also, human samples collected from ZIKV cases and controls were examined in a range of assay systems for immunological factors that might drive ZIKV neurological disease.

Using myelinating cultures, we first observed that glial cells in the central nervous system (CNS) were much more susceptible to ZIKV infection compared with cells in the peripheral nervous system (PNS),

where infection was minimal [63]. Within the CNS, myelin-forming oligodendrocytes were particularly vulnerable to infection, which induced cell death and myelin loss, accompanied by axonal degeneration in the absence of any observable injury to, or ZIKV infection of neuronal cell bodies. When early post-natal mice were infected with ZIKV *in vivo*, we again saw a propensity for oligodendrocyte infection, with relative sparing of neurons [64]. These studies collectively indicate that direct infection of peripheral nerve is unlikely to account for the development of Guillain-Barré syndrome (GBS) and that amongst the CNS manifestations of ZIKV infection clinicians should be particularly alert to de- and dys-myelinating syndromes and pathologies.

ZIKV replicates more efficiently in neural progenitor cells than in postmitotic neurons. ZikaPLAN identified host factors such as BAF45b, which regulates differentiation of neural progenitor cells to postmitotic neurons [65]. Given their function in cell and tissue differentiation, regulators such as the BAF complex may be important determinants of tropism and pathogenesis of arthropod-borne flaviviruses, which should be further investigated.

To explore the molecular mechanisms, we did genetic screens using CRISPR/Cas9 technology, mass spectrometry of pull-down assays and transcriptional analysis [66]. Genes and sets of genes identified included those involved in antiviral responses, neuroinflammation, demyelination and regulation of gene expression and differentiation. ZikaPLAN's immunological studies on clinical samples attempted to identify anti-nerve auto-immune factors, notably autoantibodies that might drive the development of GBS. The major class of previously identified GBS autoantibodies to nerve glycolipids including gangliosides do not appear to be present in ZIKV-GBS sera, despite extensive screening of multiple GBS and control cohorts [67]. Further exploration of unknown autoantigen targets in ZIKV-GBS is being pursued through screening peripheral nerve cultures, cell lines and sectioned tissues for antibody-binding events. Furthermore, T cell responses have been characterised from acute phase lymphocytes in clinical samples, along with case characterisation through arboviral screening protocols. We found that T cell responses triggered by pre-existing dengue virus infection are protective against Zika virus infection [68]. In a mouse model, specific T cells to Japanese encephalitis virus, another flavivirus, could also protect against Zika [69].

The spectrum of Zika virus-associated neurological disease

ZikaPLAN launched a specific case-control study to determine the association between GBS and ZIKV and other arbovirus infections such as chikungunya and dengue. The case-control study, named 'IGOS-

Zika', was conducted in several hospitals across Brazil, Argentina and Malaysia. To enhance harmonization of data collection of GBS patients across different study groups, the IGOS protocol was also used as template in the observational cohort study on GBS in Colombia in the Neuroviruses Emerging in the Americas Study (NEAS) [70]. ZikaPLAN was the first to identify that Zika virus infection can result in a mixed picture of both central and peripheral nervous system disease [71,72], and we reported on several rare neurological complications [73-75]. We found that whilst chikungunya virus infection was more often associated with central nervous system disease, especially myelitis, Zika was more often linked to peripheral nervous system disease, especially Guillain-Barré syndrome (GBS). We recognized a high frequency of co-infection with Zika and chikungunya virus in patients in our studies with neurological disease, underscoring the need for clinicians to investigate for evidence of both pathogens. Our study of 71 GBS cases found that almost one-third of cases had laboratory evidence of a recent infection with ZIKV or chikungunya virus [67]. Most patients with a recent arbovirus infection had a sensorimotor, demyelinating GBS. We did not find a specific anti-glycolipid antibody signature in association with arbovirus-related GBS, further elaborated upon in our systematic review [76]. During the Zika epidemic, it became apparent that no international guideline existed for the management of GBS. To aid clinicians in managing GBS patients, ZikaPLAN developed the first consensus-based international clinical guideline for the diagnosis and management of GBS [77].

In summary, ZikaPLAN contributed to the understanding of the pathomechanism of Zika virus related neurological complications and developed a 10-step guidance for the clinical management of Guillain-Barre Syndrome.

D Exploring factors that led to the emergence of congenital Zika syndrome as a public health problem

The global emergence of ZIKV revealed the unprecedented ability for a mosquito-borne virus to cause congenital birth defects such as microcephaly. Sporadic human Zika virus (ZIKV) infections have been recorded in Africa and Asia since 1950s. Major epidemics occurred only after ZIKV emerged in the Pacific Islands and spread to the Americas [78]. A puzzling aspect of ZIKV emergence is that all human outbreaks and birth defects to date have been exclusively associated with the Asian ZIKV lineage, despite a growing body of laboratory evidence pointing towards higher transmissibility and pathogenicity of the African ZIKV lineage. Whether this apparent paradox reflects the use of relatively old African

ZIKV strains in most laboratory studies was unclear. ZikaPLAN researchers assembled a panel of low-passage ZIKV strains representing the current global viral diversity to experimentally evaluate their fitness differences. ZikaPLAN found that recent African ZIKV strains largely outperformed their Asian counterparts in mosquito transmission kinetics experiments, which translated into a markedly higher epidemic potential in outbreak computer simulations [79]. In addition, African ZIKV strains were significantly more lethal than Asian ZIKV strains in immunocompromised adult mice. Finally, prenatal infection of immunocompetent mouse embryos with an African ZIKV strain resulted in embryonic death, whereas it caused microcephaly with Asian ZIKV strains. Together, these results demonstrate the high epidemic potential and pathogenicity of recent ZIKV strains from Africa. Importantly, they also imply that the African ZIKV lineage could more easily go unnoticed by public health surveillance systems than the Asian ZIKV lineage due to its propensity to cause foetal loss rather than birth defects [80].

The high epidemic potential of African ZIKV strains is counter-intuitive because continental Africa has remained free of large-scale Zika outbreaks so far. We hypothesized that this discrepancy could reflect genetic differences in the vector populations between Africa and the rest of the world. The mosquito *Aedes aegypti* is a species native to Africa that invaded most of the world's tropical belt over the past four centuries. This geographical range expansion followed the evolution of a 'domestic' form of *Ae. aegypti* that specialized in biting humans and breeding in human water-storage containers. We experimentally challenged several field-derived *Ae. aegypti* colonies from across the species range with our worldwide panel of ZIKV strains [81]. *Ae. aegypti* populations from their ancestral range in sub-Saharan Africa were significantly less susceptible to ZIKV infection, regardless of the virus strain, than the globally invasive populations from tropical America and Asia. Among the African populations, ZIKV susceptibility was positively correlated with their proportion of 'domestic' genetic ancestry. Genetic analysis of a cross between African and non-African mosquitoes further identified genomic regions associated with differences in ZIKV susceptibility. Finally, mouse studies showed that African mosquitoes were substantially less likely to transmit ZIKV from a viremic host than their non-African counterparts. These results indicate that the recent evolution and range expansion of *Ae. aegypti* outside Africa was accompanied with a marked increase in its ability to carry ZIKV. This finding may contribute to explaining why ZIKV has disproportionately caused outbreaks outside Africa.

Introduction and dispersal of ZIKV on the Pacific Islands were preceded by an extended period of relatively silent transmission in South-East Asia, enabling the virus to expand geographically and evolve adaptively before its

unanticipated introduction to immunologically naive populations on the Pacific Islands and in the Americas [82]. Specific biological determinants of the explosive epidemic nature of ZIKV have not been identified. The genetic regions of ZIKV which are most homologous to the *Aedes* spp. borne dengue viruses while three large areas within the nonstructural protein encoding regions contain sequences more similar to *Culex*-borne antigenic complex III flaviviruses such as West Nile, Japanese encephalitis and Australasian flaviviruses [78]. ZikaPLAN researchers hypothesized that this incongruence reflects interspecies recombination resulting in ZIKV evasion of cross-protective T-cell immunity. Our findings demonstrate that the ZIKV proteome is a hybrid of *Aedes*-borne dengue virus (DENV) proteins interspersed amongst *Culex*-borne flavivirus proteins derived through independent interspecies recombination events. We propose that by acquiring cytotoxic T-cell epitope-rich regions from *Culex*-borne flaviviruses, ZIKV evaded DENV-generated T-cell immune cross-protection. Thus, *Culex*-borne flaviviruses, including West Nile virus and Japanese encephalitis virus, might induce cross-protective T-cell responses against ZIKV. This would explain why explosive ZIKV epidemics occurred in DENV-endemic regions of Micronesia, Polynesia and the Americas where *Culex*-borne flavivirus outbreaks are infrequent and why ZIKV did not cause major epidemics in Asia where *Culex*-borne flaviviruses are widespread [78].

In summary, ZikaPLAN elucidated the factors that led to the emergence of congenital Zika syndrome in Latin America and not Africa.

E ZikaPLAN's research on Zika's geographic spread via international travel and its epidemic trajectory

Travellers contributed substantially to the rapid spread of ZIKV [83]. ZikaPLAN collaborated with GeoSentinel, a global surveillance network of returning travellers [84,85]. A literature review of the GeoSentinel publications related to Zika showed that Zika was first reported by GeoSentinel already in 2012, and notifications peaked in the years 2016–17 reflecting the public health emergency in the Americas at the time [86]. GeoSentinel sites reported 525 ZIKV cases from 2012 through 2019 with a clear decline in travellers after the 2016 outbreak [87]. Main countries of exposure were the Caribbean Islands and Latin America. However, Zika cases have also been described outside of the Americas [88–91] and sporadically also still occur in Latin America [92]; hence, pre-travel advice and guidance need to continue in particular, for pregnant travellers [49,93]. ZikaPLAN has developed a smartphone App-based sentinel surveillance system for (i) the assessment of the incidence of arboviral-related symptoms in

travellers and (ii) the risk assessment/modelling of travel-related introduction of arboviruses to vector-infested regions of Europe. ZikaPLAN also developed 'baited filter paper-based mosquito traps' to assess the arbovirome (i.e. to identify the spectrum of arboviruses in local mosquito populations in tropical and subtropical countries for sentinel surveillance).

Applying a spatio-temporal dynamic transmission model for ZIKV infection to determine key transmission parameters and projected incidence in 90 major cities within 35 countries, ZikaPLAN researchers together with ZIKAlliance modellers predicted that the ZIKV epidemic would be by and large over within Latin America within a matter of a year [94]. Local low levels of transmission are probable, but the estimated rate of infection suggests that most cities have a population with high levels of herd immunity. However, in 10 years as population herd immunity wanes, it is very plausible that Zika will return.

In summary, ZikaPLAN studied mobility networks and traveller's sentinel surveillance to anticipate the projected trajectory and global spread of Zika.

F ZikaPLAN's legacy with regards to enhancing research capacity and collaborative networks between Europe and Latin America

ZikaPLAN's final objective, as outlined by the European Commission in its call, was for the Zika outbreak research response effort to grow into a sustainable Latin-American network for emerging infectious diseases research preparedness. True transparent research partnerships are needed to ensure successful research and sharing of data. Such partnerships require trust, mutual benefit and sharing and equitable standing of all partners. Trust can only be built up by relationships. Relationships were fostered by EU-funded ZikaPLAN meetings, which took place every year in different ZikaPLAN sites in Brazil, Cuba, Colombia, and the UK. We engaged in capacity building in laboratory and clinical research, collaborated with existing networks to share knowledge, and set up new networks and training resources for capacity building. In the following, we describe some selected platforms, networks and web-based hubs that ZikaPLAN established

ZikaPLAN's diagnostic evaluation platform and biobanking network

Biobanking and diagnostic evaluation networks play a critical role in providing the necessary resources and mechanism to facilitate and accelerate diagnostic development and evaluation so that quality-assured tests can be deployed without delay by countries for

future pathogens of epidemic potential [95]. ZikaPLAN's goal was to accelerate the development and evaluation of Zika diagnostics for clinical and surveillance use through the establishment of a biobanking network to guarantee access to well-characterized clinical specimens and capacity for independent evaluations [3,4]. Six sites in Africa, Asia and Latin America with well-characterized clinical specimens were selected to evaluate Zika diagnostic tests using a standardised protocol (**Figure 1**). All sites are proficient in performing reference standard tests and compliant with Good Clinical Practice/ Good Clinical Laboratory Practice. ZikaPLAN partnered with UNICEF and USAID to evaluate various Zika and multiplex arbovirus diagnostic tests. Development and evaluation of diagnostics for diseases of epidemic potential are often funded during an epidemic and left unfinished once the epidemic is over when funding is no longer available. UNICEF and USAID made an advance purchase commitment with ZikaPLAN to ensure the development and availability of quality-assured diagnostics for diseases of epidemic potential. ZikaPLAN diagnostic evaluation platform has already served as a model platform for the COVID-19 pandemic [96]. The biobanking network and its governance structure were leveraged upon to evaluate SARS-CoV-2 assays [95], dengue assays and rapid diagnostic tests [97–100].

Creation of Latin American network for congenital malformation surveillance (ReLAMC)

To increase the epidemiologic surveillance in Latin America, a Latin American network of congenital malformation registries (ReLAMC) was created [61] building on the foundation of another surveillance network, ECLAMC (Estudio Colaborativo Latino Americano de Malformaciones Congénitas/ Latin American Collaborative Study of Congenital Malformations). ECLAMC is an active hospital network of birth defects registries throughout South America. ReLAMC integrates ECLAMC but expands the network of registries to include not only hospitals but also national and regional registry systems, thus enhancing the research potential for the entire continent. The ReLAMC database was based on that used by the International Clearinghouse for Birth Defects Surveillance and Research and the European Surveillance of Congenital Anomalies (EUROCAT) model for the initial design of the Terms of Agreement, data sharing options, the use of data quality and public health indicators, and web page contents, particularly prevalence. Twelve countries in the Americas are participating, including five national registries, six regional registries, and various hospitals.

International networks for investigating Guillain-Barré syndrome (GBS) and other neurological complications of arboviral diseases

ZikaPLAN built upon the International GBS Outcome Study (IGOS), the largest ongoing international observational cohort study on GBS, coordinated by Erasmus University in Amsterdam in the Netherlands [101] (<https://gbsstudies.erasmusmc.nl/>). Together with REDe, funding was acquired to create a dedicated GBS Knowledge Hub on The Global Health Network (<https://rede.tghn.org/gbs-flowchart-sample/>). Furthermore, when COVID-19 emerged as the next public health emergency of international concern, the IGOS network was leveraged upon to investigate the relationship between GBS and COVID-19, showing the ability of the IGOS network to quickly respond prepare for future outbreaks of infectious disease related to GBS [102]. The neurological networks set up through ZikaPLAN were critical in the successful application to the UK National Institute for Health Research (NIHR) for £2.3 M to establish 'Brain Infections Global' (an NIHR Global Health Research group on acute brain infections) and the subsequent Global Covid Neuro Network, established at the start of the COVID-19 pandemic. This network has applied approaches developed through ZikaPLAN to studying neurological COVID-19 disease, using standardised case definitions to harmonise data reporting [103].

Global vector hub

An early version of The Global Vector Hub (GVH) was launched in June 2020, with a full version to follow in 2021 (<https://globalvectorhub.lshtm.ac.uk/>). This open-access online platform has a repository for entomological data, resources section, and networking features intended to establish a community of practice for vector control researchers and workers. The site aims to strengthen capacity building and data sharing for vector control globally. It currently has registered users from 74 countries and datasets have a current focus on *Aedes* in South and Central America, which will expand to other geographies and mosquito species soon. The GVH has directory of more than 100 training courses in medical entomology from all WHO regions, in collaboration with WHO Special Programme for Research and Training in Tropical Diseases. GVH co-created a Massive Open Online Course (MOOC) entitled 'The Global Challenge of Vector Borne Diseases and How to Control Them', which was launched in September 2020. GVH published a topical opinion article that brought together a broad coalition of global vector experts to discuss the impact of the COVID-19 pandemic on dengue control efforts [104]. To ensure

accessibility and visibility, the GVH website is hosted by the Global Health Network.

REDe

REDe is a 'community of practice' hosted by the Global Health Network (TGHN) with the purpose to accelerate and streamline research, through a digital platform. This online science park (<https://rede.tghn.org/>) is where research groups can benefit from collaborative working, knowledge sharing and dissemination. It also provides a platform for capacity development and resources. The flagship area for capacity development is the training centre, with 250,000 modules taken, embedded within the Global Health Trials section of the platform. A resource of particular interest for research methodology is the 'Process Map' toolkit, which currently provides systematic guidance for planning global health research projects and is being repurposed for use in tracking new studies. REDe also fosters collaboration within ZikaPLAN, which led to three knowledge hubs launched within TGHN (where REDe is hosted); Brain Infections Global, Global Birth Defects and The Global Vector Hub (Table 1). Online training has been successful with over 265,000 research skills courses taken regionally and 17 new courses have been developed with the University of Liverpool on identifying and diagnosing a range of neurological infectious diseases. Many of these resources and courses are available in Spanish and Portuguese to maximise utility and accessibility. To ensure further capacity building beyond the ZikaPLAN funding period, a memorandum of understanding was signed with Fiocruz, Brazil, to continue making training courses and resources freely available.

Dissemination

In collaboration with all our consortium members and new networks, three different on-line dissemination events were organized towards the end of the ZikaPLAN project (<https://zikaplan.tghn.org/zikaplan-tools/webinars/>). In addition, four thematic videos (Table 2) were released in April 2021, summarizing the legacy of ZikaPLAN with its aim to enhance a sustainable Latin American research preparedness network.

In summary, ZikaPLAN has created a network of networks for capacity building across various disciplines and to ensure sustainability.

Outlook

While the Zika virus pandemic has ended, the devastating health and social impacts on children with CZS and their families continue. The world cannot forget these affected families and communities, even now

when the COVID-19 pandemic is drawing all our attention. We need to continue to advocate for effective support services for children with CZS and their families. As ZikaPLAN's 5-year funding period has come to an end, renewed funding will be needed to continue monitoring the unique infant cohort that ZikaPLAN, ZIKAlliance and ZIKAction successfully set up through EU funding. There is a public health imperative to follow up on the neurodevelopment milestones and get a better grasp of the long-term physical and socioeconomic consequences of Zika-affected children when these children turn 5 and older. Furthermore, the world needs to be prepared for a likely return of Zika [105]. ZikaPLAN has developed animal models for future research on Zika-specific therapeutics and Zika vaccine candidates [106] [107–109], Zika vaccine development must continue even in the absence of major Zika virus circulation so that the world has tools at hand should Zika re-emerge [110,111].

Dedication

This manuscript is dedicated to Professor Peter Byass who sadly passed away on 17 August 2020. He was instrumental in setting up the first EU-funded dengue research consortium hosted by the Umeå Centre of Global Health Research, Umeå University, Sweden. Through the established networks of DengueTools, we were able to rapidly re-create and broaden a related consortium – the Zika research consortium ZikaPLAN – as soon as Zika was declared a public health emergency of international concern. In fact, much of the proposal writing for ZikaPLAN took place in Peter's home in mid-April 2016. We are thankful for the guidance received by Professor Byass during the proposal writing, and the warm hospitality by Mrs Byass during the stay.

Acknowledgments

We acknowledge the Department of Epidemiology and Global Health of Umeå University, Sweden for hosting the ZikaPLAN consortium, and express our appreciation for the extremely professional and always friendly project office. We thank all our consortium members and their institutions, and we are thankful to many other institutional staff members (all the administrators and financial managers) who participated and supported the implementation of the ZikaPLAN project in different capacities. Our special thanks to Prof Laura Rodrigues from the London School of Hygiene & Tropical Medicine, UK, for her pioneering spirit, foresight and epidemiological acumen in setting up the Microcephaly Epidemic Research Group (MERG) together with many ZikaPLAN colleagues in Brazil very early on in the Zika epidemic even before EU funding was available. We would like to thank Koren Wolman-Tardy and Margaux Luciani for their professional approach to developing videos, organizing the

dissemination events, and coordinating the ZikaPLAN newsletters and website. We are grateful to our Scientific Advisory Board members (Duane Gubler, James Sejvar, Herman Goossens) and Ethics Advisory Committee member (Anna Durbin) for their timely support and guidance at various stages of the project. We deeply appreciate our collaborative work with ZIKAction (Grant Agreement No. 734857) and ZIKAlliance (Grant Agreement No. 734548) which allowed us in collectively advancing common efforts and strengthening the research output as one voice creating larger impact thereby setting an example of collaboration and data sharing.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding information

This project, ZikaPLAN is funded by the European Union's Horizon 2020 research and innovation programme under Grant Agreement No. h2020 health 734584. Some authors have received additional research funding. The Microcephaly Epidemic Research Group (MERG) has received additional funding from Wellcome Trust UK, Department for International Development UK, Medical Research Council UK, the Brazilian funding through CNPq, Secretaria de Vigilância de Saúde (SVS), and Fundação do Amparo a Ciência e Tecnologia (FACEPE). LT is supported by a Wellcome Trust fellowship [205228/Z/16/Z]. The Latin American Congenital Malformations Network (ReLAMC) group has received additional Brazilian funding through DECIT, CNPq (440614/2016-3), and CAPES (88887.130724/2016-00, 88887.130724/2016-00)

Author contributions

AWS, the Scientific Coordinator of ZikaPLAN, wrote the manuscript; all authors contributed in their respective fields of expertise as the work package leaders or as the significant task leaders of ZikaPLAN. All authors read and approved the final manuscript.

Ethics and consent

Ethics clearances were sought in the institutional review boards of the countries where the research is taking place. The European Commission performed a mid-term Ethics Compliance to ensure all institutions involved are following the regulations, locally, nationally and/or internationally.


Paper context

Global health research partnerships with institutions from high-income countries and low- and middle-income countries are one of the European Commission's flagship programmes. Here, we report on the ZikaPLAN research consortium funded by the European Commission by highlighting main achievements and outputs that will lead to the legacy of ZikaPLAN.

ORCID

Annelies Wilder-Smith  <http://orcid.org/0000-0003-0362-5375>

Elizabeth B. Brickley  <http://orcid.org/0000-0003-0280-2288>

Demócrito de Barros Miranda-Filho  <http://orcid.org/0000-0003-2537-1476>

Carlos A. Pardo  <http://orcid.org/0000-0002-4128-5335>

Hugh J Willison  <http://orcid.org/0000-0002-5997-1683>

Louis Lambrechts  <http://orcid.org/0000-0001-5958-2138>

Johan Neyts  <http://orcid.org/0000-0002-0033-7514>

Suzanne Kaptein  <http://orcid.org/0000-0002-7935-0219>

Helen Dolk  <http://orcid.org/0000-0001-6639-5904>

Ieda M Orioli  <http://orcid.org/0000-0003-1863-6229>

References

- [1] Pratt B, Hyder AA. Governance of Transnational Global Health Research Consortia and Health Equity. *Am J Bioeth.* 2016 Oct;16:29–45.
- [2] Wilder-Smith A, Osman S. Public health emergencies of international concern: a historic overview. *J Travel Med.* 2020 Dec 23; 27. DOI:10.1093/jtm/taaa227.
- [3] Wilder-Smith A, Preet R, Renhorn KE, et al. ZikaPLAN: zika Preparedness Latin American Network. *Glob Health Action.* 2017;10:1398485.
- [4] Wilder-Smith A, Preet R, Brickley EB, et al. ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas. *Glob Health Action.* 2019;12:1666566.
- [5] Lowe R, Barcellos C, Brasil P, et al. The Zika Virus Epidemic in Brazil: from Discovery to Future Implications. *Int J Environ Res Public Health.* 2018 Jan 9;15. DOI:10.3390/ijerph15010096
- [6] Brickley EB, Rodrigues LC. Further pieces of evidence in the Zika virus and microcephaly puzzle. *Lancet Child Adolesc Health.* 2018 ;2:162–164.
- [7] de Araujo TVB, Ximenes RAA, Miranda-Filho DB, et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. *Lancet Infect Dis.* 2018 Mar;18:328–336.
- [8] de Araujo TVB, Rodrigues LC DAXRA, et al. Association between Zika virus infection and microcephaly in Brazil, January to May, 2016: preliminary report of a case-control study. *Lancet Infect Dis.* 2016 Dec;16:1356–1363.
- [9] Brasil P, Pereira JP Jr., Moreira ME, et al. Zika Virus Infection in Pregnant Women in Rio de Janeiro. *N Engl J Med.* 2016 Dec 15;375:2321–2334.
- [10] Albuquerque MF, Souza WV, Mendes AD, et al. Pyriproxyfen and the microcephaly epidemic in Brazil - an ecological approach to explore the hypothesis of their association. *Mem Inst Oswaldo Cruz.* 2016 Dec;111:774–776.
- [11] Dde B M-F, Martelli CM, Ximenes RA, et al. Initial Description of the Presumed Congenital Zika Syndrome. *Am J Public Health.* 2016 Apr;106:598–600.
- [12] Albuquerque M, Souza WV, Araujo TVB, et al. The microcephaly epidemic and Zika virus: building knowledge in epidemiology. *Cad Saude Publica.* 2018 Oct 11;34:e00069018.
- [13] Castanha PMS, Souza WV, Braga C, et al. Perinatal analyses of Zika- and dengue virus-specific neutralizing antibodies: a microcephaly case-control study in an area of high dengue endemicity in Brazil. *PLoS Negl Trop Dis.* 2019 Mar;13:e0007246.
- [14] Ximenes RAA, Miranda-Filho DB, Brickley EB, et al. Zika virus infection in pregnancy: establishing a case definition for clinical research on pregnant women with rash in an active transmission setting. *PLoS Negl Trop Dis.* 2019 Oct;13:e0007763.
- [15] Ximenes RAA, Miranda-Filho DB, Montarroyos UR, et al. Zika Related Adverse Outcomes in a Cohort of Pregnant Women with Rash in Pernambuco, Brazil. *PLoS Negl Trop Dis.* 2021 [In Press];15:e0009216.
- [16] Sobhani NC, Avvad-Portari E, Nascimento ACM, et al. Discordant Zika Virus Findings in Twin Pregnancies Complicated by Antenatal Zika Virus Exposure: a Prospective Cohort. *J Infect Dis.* 2020 May 11;221:1838–1845.
- [17] Pereira JP, Nielsen-Saines K, Sperling J, et al. Association of Prenatal Ultrasonographic Findings With Adverse Neonatal Outcomes Among Pregnant Women With Zika Virus Infection in Brazil. *JAMA Network Open.* 2018;1:e186529. cited e186529 p.]. <http://europepmc.org/abstract/MED/30646333> <https://doi.org/10.1001/jamanetworkopen.2018.6529> <https://europepmc.org/articles/PMC6324324>
- [18] Pereira JP, Maykin MM, Vasconcelos Z, et al. The Role of Amniocentesis in the Diagnosis of Congenital Zika Syndrome. *Clin Infect Dis.* 2019;69:713–716.
- [19] Brasil P, Vasconcelos Z, Kerin T, et al. Zika virus vertical transmission in children with confirmed antenatal exposure. *Nat Commun.* 2020 Jul 14;11:3510.
- [20] Souza JP, Meio M, de Andrade LM, et al. Adverse fetal and neonatal outcomes in pregnancies with confirmed Zika Virus infection in Rio de Janeiro, Brazil: a cohort study. *PLoS Negl Trop Dis.* 2021 Jan;15:e0008893.
- [21] Sanchez Clemente N, Brickley EB, Paixao ES, et al. Zika virus infection in pregnancy and adverse fetal outcomes in Sao Paulo State, Brazil: a prospective cohort study. *Sci Rep.* 2020 Jul 29;10:12673.
- [22] Power GM, Francis SC, Sanchez Clemente N, et al. Examining the Association of Socioeconomic Position with Microcephaly and Delayed Childhood Neurodevelopment among Children with Prenatal Zika Virus Exposure. *Viruses.* 2020 Nov 23;12:1342.
- [23] Souza WV, Albuquerque M, Vazquez E, et al. Microcephaly epidemic related to the Zika virus and living conditions in Recife, Northeast Brazil. *BMC Public Health.* 2018 Jan 12;18:130.
- [24] Microcephaly Epidemic Research G. Microcephaly in Infants, Pernambuco State, Brazil. *Emerg Infect Dis.* *Emerg Infect Dis.* 2016 Jun;22 :1090–1093.
- [25] Pires P, Jungmann P, Galvao JM, et al. Neuroimaging findings associated with congenital Zika virus syndrome: case series at the time of first epidemic outbreak in Pernambuco State, Brazil. *Childs Nerv Syst.* 2018 May;34:957–963.
- [26] Hazin AN, Poretti A, Di Cavalcanti Souza Cruz D, et al. Computed Tomographic Findings in Microcephaly Associated with Zika Virus. *N Engl J Med.* 2016 Jun 2;374:2193–2195.
- [27] Oliveira D, Miranda-Filho DB, Ximenes RAA, et al. Comparison of Oropharyngeal Dysphagia in

- Brazilian Children with Prenatal Exposure to Zika Virus, With and Without Microcephaly. *Dysphagia*. 2020 Sep 4;36:583–594.
- [28] Carvalho M, Ximenes RAA, Montarroyos UR, et al. Early epilepsy in children with Zika-related microcephaly in a cohort in Recife, Brazil: characteristics, electroencephalographic findings, and treatment response. *Epilepsia*. 2020 Mar;61:509–518.
- [29] Carvalho M, Miranda-Filho DB, van der Linden V, et al. Sleep EEG patterns in infants with congenital Zika virus syndrome. *Clin Neurophysiol*. 2017 Jan;128:204–214.
- [30] de Vasconcelos RAL, Ximenes RAA, Calado AA, et al. Cryptorchidism in Children with Zika-Related Microcephaly. *Am J Trop Med Hyg*. 2020 May;102:982–984.
- [31] de Vasconcelos Ral, Ximenes RAA, Calado AA, et al. Surgical findings in cryptorchidism in children with Zika-related microcephaly: a case series. *BMC Urol*. 2020 Nov 23;20:186.
- [32] Veras Goncalves A, Miranda-Filho DB, Rocha Vilela LC, et al. Endocrine Dysfunction in Children with Zika-Related Microcephaly Who Were Born during the 2015 Epidemic in the State of Pernambuco, Brazil. *Viruses*. 2020 Dec 22;13:1.
- [33] Leal MC, Seabra Ramos D, Pinto Bezerra T, et al. The Prevalence of Adenoid Hypertrophy among Children with Zika Related Microcephaly. *Viruses*. 2021 Jan 5;13:62.
- [34] Adachi K, Romero T, Nielsen-Saines K, et al. Early Clinical Infancy Outcomes for Microcephaly and/or Small for Gestational Age Zika-Exposed Infants. *Clin Infect Dis*. 2020;70:2663–2672.
- [35] Cranston JS, Tiene SF, Nielsen-Saines K, et al. Association Between Antenatal Exposure to Zika Virus and Anatomical and Neurodevelopmental Abnormalities in Children. *JAMA Network Open*. 2020 Jul 1;3:e209303.
- [36] Einspieler C, Utsch F, Brasil P, et al. Association of Infants Exposed to Prenatal Zika Virus Infection With Their Clinical, Neurologic, and Developmental Status Evaluated via the General Movement Assessment Tool. *JAMA Network Open*. 2019;2:]. cited e187235 <http://europepmc.org/abstract/MED/30657537> <https://doi.org/10.1001/jamanetworkopen.2018.7235> <https://europepmc.org/articles/PMC6431234>
- [37] Dos Santos SFM, Soares FVM DAAD, et al. Nutritional profile of newborns with microcephaly and factors associated with worse outcomes. *Clinics (Sao Paulo)*. cited e798 p.]. DOI:10.6061/clinics/2019/e798 <http://europepmc.org/abstract/MED/31644665> <https://doi.org/10.6061/clinics/2019/e798> <https://europepmc.org/articles/PMC6791297> <https://europepmc.org/articles/PMC6791297?pdf=render>. 2019;74: .
- [38] Soares F, Abranches AD, Villela L, et al. Zika virus infection in pregnancy and infant growth, body composition in the first three months of life: a cohort study. *Sci Rep*. 2019 Dec 16;9:19198.
- [39] Dos Santos SFM, Soares FVM, de Abranches AD, et al. Infants with microcephaly due to ZIKA virus exposure: nutritional status and food practices. *Nutr J*. 2019;18:]. cited 4 <http://europepmc.org/abstract/MED/30634976> <https://doi.org/10.1186/s12937-019-0429-3> <https://europepmc.org/articles/PMC6330418>
- <https://europepmc.org/articles/PMC6330418?pdf=render>
- [40] Da Silva Pf S, Eickmann SH, de Alencar Ximenes R A, et al. Pediatric neurodevelopment by prenatal Zika virus exposure: a cross-sectional study of the Microcephaly Epidemic Research Group Cohort. *BMC Pediatr*. 2020 Oct 10;20:472.
- [41] Lopes Moreira ME, Nielsen-Saines K, Brasil P, et al. Neurodevelopment in Infants Exposed to Zika Virus In Utero. *N Engl J Med*. 2018 Dec 13;379:2377–2379.
- [42] Pecanha PM, Gomes Junior SC, Pone SM, et al. Neurodevelopment of children exposed intra-uterus by Zika virus: a case series. *PLoS One*. 2020;15: e0229434.
- [43] Kuper H, Lyra TM, Moreira MEL, et al. Social and economic impacts of congenital Zika syndrome in Brazil: study protocol and rationale for a mixed-methods study. *Wellcome Open Res*. 2018;3:127.
- [44] Moreira MCN, Nascimento M, Mendes CHF, et al. Emergency and permanence of the Zika virus epidemic: an agenda connecting research and policy. *Cad Saude Publica*. 2018 Aug 20;34:e00075718.
- [45] de Melo APL, Lyra T, de Araujo TVB, et al. “Life Is Taking Me Where I Need to Go”: biographical Disruption and New Arrangements in the Lives of Female Family Carers of Children with Congenital Zika Syndrome in Pernambuco, Brazil. *Viruses*. 2020 Dec 8;12:1410.
- [46] Albuquerque MSV, Lyra TM, Melo APL, et al. Access to healthcare for children with Congenital Zika Syndrome in Brazil: perspectives of mothers and health professionals. *Health Policy Plan*. 2019 Sep 1;34:499–507.
- [47] Simas C, Penn-Kekana L, Kuper H, et al. Hope and trust in times of Zika: the views of caregivers and healthcare workers at the forefront of the epidemic in Brazil. *Health Policy Plan*. 2020 Oct 1;35:953–961.
- [48] Kuper H, Lopes Moreira ME, Barreto de Araujo TV, et al. The association of depression, anxiety, and stress with caring for a child with Congenital Zika Syndrome in Brazil; Results of a cross-sectional study. *PLoS Negl Trop Dis*. 2019 Sep;13:e0007768.
- [49] Vouga M, Chiu YC, Pomar L, et al. Dengue, Zika and chikungunya during pregnancy: pre- and post-travel advice and clinical management. *J Travel Med*. 2019 Dec 23;26 : 8 .
- [50] Mendoza C, Jaramillo GI, Ant TH, et al. An investigation into the knowledge, perceptions and role of personal protective technologies in Zika prevention in Colombia. *PLoS Negl Trop Dis*. 2020 Jan;14: e0007970.
- [51] Lobkowicz L, Ramond A, Sanchez Clemente N, et al. The frequency and clinical presentation of Zika virus coinfections: a systematic review. *BMJ Glob Health*. 2020;5:e002350.
- [52] Ramond A, Lobkowicz L, Clemente NS, et al. Postnatal symptomatic Zika virus infections in children and adolescents: a systematic review. *PLoS Negl Trop Dis*. 2020;14:e0008612. cited e0008612 p.]. <http://europepmc.org/abstract/MED/33006989> <https://doi.org/10.1371/journal.pntd.0008612> <https://europepmc.org/articles/PMC7556487> <https://europepmc.org/articles/PMC7556487?pdf=render>
- [53] Passos MJ, Matta G, Lyra TM, et al. The promise and pitfalls of social science research in an emergency:

- lessons from studying the Zika epidemic in Brazil, 2015-2016. *BMJ Glob Health*. 2020;5:e002307.
- [54] Clemente NS, Ramond A, Turchi Martelli CM, et al. Geographies of risk: emerging infectious diseases and travel health data. *Travel Med Infect Dis*. 2020 Jul;36:101806.
- [55] Brickley EB, Paixao ES. Covid-19: the time to shield all pregnant frontline workers is now. *BMJ*. 2020 May 4;369:m1792.
- [56] Alecrim M, Amorim MMR, Araujo TVB, et al. Zika Brazilian Cohorts (ZBC) Consortium: protocol for an Individual Participant Data Meta-Analysis of Congenital Zika Syndrome after Maternal Exposure during Pregnancy. *Viruses*. 2021 Apr 16;13:687.
- [57] Ades AE, Brickley EB, Alexander N, et al. Zika virus infection in pregnancy: a protocol for the joint analysis of the prospective cohort studies of the ZIKAlliance, ZikaPLAN and ZIKAction consortia. *BMJ Open*. 2020 Dec 15;10:e035307.
- [58] Wilder-Smith A, Wei Y, Araujo TVB, et al. Understanding the relation between Zika virus infection during pregnancy and adverse fetal, infant and child outcomes: a protocol for a systematic review and individual participant data meta-analysis of longitudinal studies of pregnant women and their infants and children. *BMJ Open*. 2019 Jun 18;9:e026092.
- [59] Zika Virus Individual Participant Data C. The Zika Virus Individual Participant Data Consortium: a Global Initiative to Estimate the Effects of Exposure to Zika Virus during Pregnancy on Adverse Fetal, Infant, and Child Health Outcomes. *Trop Med Infect Dis*. 2020 Sep 30;51: 152 .
- [60] Dolk H, Leke AZ, Whitfield P, et al. Global birth defects app: an innovative tool for describing and coding congenital anomalies at birth in low resource settings. *Birth Defects Res*. 2021 May 5;113:1057–1073.
- [61] Orioli IM, Dolk H, Lopez-Camelo J, et al. The Latin American network for congenital malformation surveillance: reLAMC. *Am J Med Genet C Semin Med Genet*. 2020 Dec;184:1078–1091.
- [62] Morris JK, Dolk H, Duran P, et al. Use of infectious disease surveillance reports to monitor the Zika virus epidemic in Latin America and the Caribbean from 2015 to 2017: strengths and deficiencies. *BMJ Open*. 2020 Dec 12;10:e042869.
- [63] Cumberworth SL, Barrie JA, Cunningham ME, et al. Zika virus tropism and interactions in myelinating neural cell cultures: CNS cells and myelin are preferentially affected. *Acta Neuropathol Commun*. 2017 Jun 23;5:50.
- [64] Schultz V, Barrie JA, Donald CL, et al. Oligodendrocytes are susceptible to Zika virus infection in a mouse model of perinatal exposure: implications for CNS complications. *Glia*. 2021 Aug;69:2023–2036.
- [65] Persson BD, Nord S, Lindqvist R, et al. BAF45b Is Required for Efficient Zika Virus Infection of HAP1 Cells. *Viruses*. 2021;13:2007.
- [66] Schultz V, Cumberworth SL, Gu Q, et al. Zika Virus Infection Leads to Demyelination and Axonal Injury in Mature CNS Cultures. *Viruses*. 2021 Jan 11;13:91.
- [67] Leonhard SE, Halstead S, Lant SB, et al. Guillain-Barre syndrome during the Zika virus outbreak in Northeast Brazil: an observational cohort study. *J Neurol Sci*. 2021 Jan 15;420:117272.
- [68] Grifoni A, Pham J, Sidney J, et al. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. *J Virol*. 2017 Dec 15;91. DOI:10.1128/JVI.01469-17
- [69] Wang R, Zhen Z, Turtle L, et al. T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. *Appl Microbiol Biotechnol*. 2020 Aug;104:6779–6789.
- [70] Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-Barre Syndrome Associated with Zika Virus Infection in Colombia. *N Engl J Med*. 2016 Oct 20;375:1513–1523.
- [71] Mehta R, Soares CN, Medialdea-Carrera R, et al. The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: a case series. *PLoS Negl Trop Dis*. 2018 Feb;12:e0006212.
- [72] Brito Ferreira ML, Militao de Albuquerque Mfp DBCAA, et al. Neurological disease in adults with Zika and chikungunya virus infection in Northeast Brazil: a prospective observational study. *Lancet Neurol*. 2020 Oct;19:826–839.
- [73] Rueda-Lopes FC, Soares CN, Vieira IF, et al. Bilateral median nerve neuritis after chikungunya virus infection. *Lancet Infect Dis*. 2020 Mar;20:382.
- [74] Leonhard SE, Munts AG, van der Eijk AA, et al. Acute-onset chronic inflammatory demyelinating polyneuropathy after Zika virus infection. *J Neurol Neurosurg Psychiatry*. 2018 Oct;89:1118–1119.
- [75] Aspahan MC, Leonhard SE, Gomez RS, et al. Neuromyelitis optica spectrum disorder associated with Zika virus infection. *Neurol Clin Pract*. 2019 Feb;9:e1–e3.
- [76] Leonhard SE, Bresani-Salvi CC, Lyra Batista JD, et al. Guillain-Barre syndrome related to Zika virus infection: a systematic review and meta-analysis of the clinical and electrophysiological phenotype. *PLoS Negl Trop Dis*. 2020 Apr;14:e0008264.
- [77] Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barre syndrome in ten steps. *Nat Rev Neurol*. 2019 Nov;15:671–683.
- [78] Gaunt MW, Gubler DJ, Pettersson JH, et al. Recombination of B- and T-cell epitope-rich loci from Aedes- and Culex-borne flaviviruses shapes Zika virus epidemiology. *Antiviral Res*. 2020 Feb;174:104676.
- [79] Aubry F, Jacobs S, Darmuzey M, et al. Recent African strains of Zika virus display higher transmissibility and fetal pathogenicity than Asian strains. *Nat Commun*. 2021 Feb 10;12:916.
- [80] Lambrechts L. Did Zika virus attenuation or increased virulence lead to the emergence of congenital Zika syndrome? *J Travel Med*. 2021 Mar 23; 28. DOI:10.1093/jtm/taab041.
- [81] Aubry F, Dabo S, Manet C, et al. Enhanced Zika virus susceptibility of globally invasive Aedes aegypti populations. *Science*. 2020 Nov 20;370:991–996.
- [82] Pettersson JH, Bohlin J, Dupont-Rouzeyrol M, et al. Re-visiting the evolution, dispersal and epidemiology of Zika virus in Asia. *Emerg Microbes Infect*. 2018 May 9;7:79.
- [83] Wilder-Smith A, Chang CR, Leong WY. Zika in travellers 1947-2017: a systematic review. *J Travel Med*. 2018 Jul 1; 25. DOI:10.1093/jtm/tay044.

- [84] Wilder-Smith A, Boggild AK. Sentinel Surveillance in Travel Medicine: 20 Years of GeoSentinel Publications (1999-2018). *J Travel Med.* 2018 Jan 1; 25. DOI:10.1093/jtm/tay139.
- [85] Hamer DH, Rizwan A, Freedman DO, et al. GeoSentinel: past, present and future dagger. *J Travel Med.* 2020 Dec 23;27. DOI:10.1093/jtm/taaa219
- [86] Osman S, Preet R. Dengue, chikungunya and Zika in GeoSentinel surveillance of international travellers: a literature review from 1995 to 2020. *J Travel Med.* 2020 Dec 23; 27. DOI:10.1093/jtm/taaa222.
- [87] Angelo KM, Stoney RJ, Brun-Cottan G, et al. Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice. *J Travel Med.* 2020 Jul 14;27. DOI:10.1093/jtm/taaa061
- [88] Hamer DH, Chen LH. Zika in Angola and India. *J Travel Med.* 2019 Feb 11; 26. DOI:10.1093/jtm/taz012.
- [89] Biswas A, Kodan P, Gupta N, et al. Zika outbreak in India in 2018. *J Travel Med.* 2020 Jul 14;27. DOI:10.1093/jtm/taaa001
- [90] Wang G, Zheng W, Zhu S, et al. A cluster of Zika virus infection among travellers returning to China from Samoa: a case tracing study. *J Travel Med.* 2018 Jan 1;25. DOI:10.1093/jtm/tay022
- [91] Leshem E, Lustig Y, Brosh-Nissimov T, et al. Incidence of laboratory-confirmed Zika in Israeli travelers to Thailand: 2016-2019. *J Travel Med.* 2019 Oct 14;26. DOI:10.1093/jtm/taz057
- [92] Akrami KM, de Nogueira BMF, Do Rosario MS, et al. The re-emergence of Zika in Brazil in 2020: a case of Guillain Barre Syndrome during the low season for arboviral infections. *J Travel Med.* 2020 Nov 9;27. DOI:10.1093/jtm/taaa165
- [93] Chen LH, Hamer DH. Zika virus and sexual transmission: updated preconception guidance. *J Travel Med.* 2018 Jan 1; 25. DOI:10.1093/jtm/tay095.
- [94] O'Reilly KM, Lowe R, Edmunds WJ, et al. Projecting the end of the Zika virus epidemic in Latin America: a modelling analysis. *BMC Med.* 2018 Oct 3;16:180.
- [95] Peeling RW, Boeras D, Wilder-Smith A, et al. Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. *Lancet Infect Dis.* 2020 Oct;20:e268–e273.
- [96] Accessed 25 May 2021 Available from: <https://afri.cacdc.org/download/establishment-of-a-biobanking-network-as-a-sustainable-mechanism-to-accelerate-development-and-evaluation-of-diagnostic-tests-in-africa/>
- [97] Goncalves A, Peeling RW, Chu MC, et al. Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: a Meeting Report. *J Infect Dis.* 2018 Mar 13;217:1060–1068.
- [98] Wilder-Smith A, Peeling RW. Optimising dengue pre-vaccination screening. *Lancet Infect Dis.* 2021 Apr;21:442–444.
- [99] Fongwen N, Wilder-Smith A, Gubler DJ, et al. Target product profile for a dengue pre-vaccination screening test. *PLoS Negl Trop Dis.* 2021 Jul;15:e0009557.
- [100] Hunsperger E, Peeling R, Gubler DJ, et al. Dengue pre-vaccination serology screening for the use of Dengvaxia(R). *J Travel Med.* 2019 Dec 23;26. DOI:10.1093/jtm/taz092
- [101] Jacobs BC, van Den Berg B, Verboon C, et al. International Guillain-Barre Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barre syndrome. *J Peripher Nerv Syst.* 2017 Jun;22:68–76.
- [102] Leonhard SE, Cornblath DR, Endtz HP, et al. Guillain-Barre syndrome in times of pandemics. *J Neurol Neurosurg Psychiatry.* 2020 Oct;91:1027–1029.
- [103] Ellul MA, Benjamin L, Singh B, et al. Neurological associations of COVID-19. *Lancet Neurol.* 2020 Sep;19:767–783.
- [104] Seelig F, Bezerra H, Cameron M, et al. The COVID-19 pandemic should not derail global vector control efforts. *PLoS Negl Trop Dis.* 2020 Aug;14:e0008606.
- [105] Lessler J, Chaisson LH, Kucirka LM, et al. Assessing the global threat from Zika virus. *Science.* 2016 Aug 12;353:aaf8160.
- [106] Jacobs S, Delang L, Verbeken E, et al. A Viral Polymerase Inhibitor Reduces Zika Virus Replication in the Reproductive Organs of Male Mice. *Int J Mol Sci.* 2019 Apr 29;20:2122.
- [107] Gladwyn-Ng I, Cordon-Barris L, Alfano C, et al. Stress-induced unfolded protein response contributes to Zika virus-associated microcephaly. *Nat Neurosci.* 2018 Jan;21:63–71.
- [108] Kum DB, Boudewijns R, Ma J, et al. A chimeric yellow fever-Zika virus vaccine candidate fully protects against yellow fever virus infection in mice. *Emerg Microbes Infect.* 2020;9:520–533.
- [109] Kum DB, Mishra N, Boudewijns R, et al. A yellow fever-Zika chimeric virus vaccine candidate protects against Zika infection and congenital malformations in mice. *NPJ Vaccines.* 2018;3:56.
- [110] Vannice KS, Casseti MC, Eisinger RW, et al. Demonstrating vaccine effectiveness during a waning epidemic: a WHO/NIH meeting report on approaches to development and licensure of Zika vaccine candidates. *Vaccine.* 2019 Feb 4;37:863–868.
- [111] Wilder-Smith A, Vannice K, Durbin A, et al. Zika vaccines and therapeutics: landscape analysis and challenges ahead. *BMC Med.* 2018 Jun 6;16:84.